The drug shortage is a creeping problem that is not noticed by the majority of patients and practitioners, even when they have been affected. No one is tracking it or its impact. Death certificates name diseases as the cause of death, not a lack of treatment.
Drug substitutions often pass unnoticed. A newer, more expensive drug might actually be thought of as better. But that is not always true. See Story 15 at this site for an example. Patients should always demand an explanation from doctors and pharmacists if their drugs are changed.
The biggest consequence, so far in Canada, is on the taxpayer. No one is measuring the extent or impact of the crisis. Death certificates require the cause of death to be a disease — not a shortage of treatment for that disease.
But in the United States, the outbreak of meningitis resulting in dozens of deaths was caused by a injectable made by compounding pharmacies and laced with fungus; it was a direct consequence of the drug shortage (see here). A study released in December 2012 shows that children with leukemia treated with substitute drugs owing to the drug shortage have a higher rate of relapse (see here and here). In 2010 Dr. William Schubert died of a shortage of the drug used to treat his rare condition, Fabry’s disease (see here). Substitute drugs also lead to errors–sometimes fatal– because concentrations, doses, and volumes change (see here).
Seniors, people in hospital, and people on welfare, all have their drugs paid for by the Canadian taxpayer. As long as they are receiving necessary treatment, they are unlikely to complain about a more expensive substitute.
People fortunate enough to have drug plans through their employers will similarly not notice, although eventually their insurance premiums will rise.
The working poor are most likely to be affected in terms of their health, because they may be unable to afford more they expensive substitutes. If they stop taking (for example) their blood pressure or diabetes or antidepressant medications, they will end up sick and in hospital. In Canada, that again means that the taxpayer and the economy will suffer.
An early 2012 report in the CMAJ shows that about 10 per cent of Canadians do not fill their prescriptions because they cannot afford the medications. Those most affected are people in poor health, the working poor, those without drug plans, and residents of British Columbia.
The problem is also hidden by silo-ing in disease categories of drugs. The Media page shows how a flurry of public attention has emerged when a certain category of drug disappears–antidepressants, anesthetics, anticonvulsants, antibiotics, and cancer chemotherapy. Those affected do not realize that their own painful shortage is part of a more serious problem affecting all drugs worldwide.
An acute crisis in February-March 2012, has led to a search for replacements and fast-tracking of approvals, but the replacement drugs will inevitably cost us more.
While activity around solving access to certain types of drugs is important for individuals, it does not address the root causes of the problem and serves to perpetuate it. It raises further questions.
With its technology and its wealth, why is Canada not an attractive location for a new Canadian-owned manufacturer of generic drugs to replace those in chronic short supply? Why must we be buffeted about by shortages, mostly originating in other countries, within an industry that largely does not belong to Canadians, concerning products, the recipes for which are neither secret nor protected?
Perhaps rather than asking Health Canada, these questions should be addressed to ministries of Industry and Foreign Affairs.
Ask your MP.